Alterations in Cell Cycle Genes in Early Stage Lung Adenocarcinoma Identified by Expression Profiling

In normal lung epithelial cells, cellular division is an ordered, tightly regulated process involving multiple checkpoints that assess extracellular growth signals, cell size, and DNA integrity. In contrast, neoplastic lung cells develop the ability to bypass several of these checkpoints, particularly at the G1/S and G2/M boundaries. We used genomic profiling to compare gene expression levels in early stage lung adenocarcinomas and non-neoplastic pulmonary tissue in order to comprehensively identify alterations in the process of cell cycling. RNA extracted from node negative, poorly differentiated lung adenocarcinomas (15 patients) and non-neoplastic pulmonary tissue (5 patients) was hybridized to oligonucleotide microarray filters containing 44,363 genes. Ontological classification was used to extract genes involved with cell cycle progression. Further analysis discovered a subset of differentially expressed genes for further study. Of the 624 cell cycle genes on the microarray filters, 40 genes were predicted to be differentially expressed in lung adenocarcinomas. Alterations in several genes (ie. cyclin B1, cyclin D1, p21, MDM2) are consistent with published data in the literature. We also identified 19 novel genes that have neither been described in non-small cell lung cancer (ie. cdc2, cullin 4A, ZAC, p57, DP-1, GADD45, PISSLRE, cdc20) nor in any other tumors (ie. cyclin F, cullin 5, p34). These results identified several potential cell cycle genes altered in lung cancer.

[1]  M. Tschan,et al.  Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. , 1998, Oncogene.

[2]  Q. Zhan,et al.  Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. , 2002, Molecular immunology.

[3]  Q. Zhan,et al.  The mismatch repair system is required for S-phase checkpoint activation , 2003, Nature Genetics.

[4]  J. H. Lee,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1999.0661 , 2022 .

[5]  E. Carosella,et al.  Human CDK10 gene isoforms. , 2000, Biochemical and biophysical research communications.

[6]  Margaret Kasten,et al.  Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity , 2001, Oncogene.

[7]  J. Minna,et al.  Molecular genetics of lung cancer. , 1988, Annual review of medicine.

[8]  K. Nagashima,et al.  Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. , 2001, Lung cancer.

[9]  Pierre Baldi,et al.  A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes , 2001, Bioinform..

[10]  C. Markopoulos,et al.  The prognostic value of alpha-thymosins in breast cancer. , 1998, Anticancer research.

[11]  Sunil Singhal,et al.  Gene expression profiling of malignant mesothelioma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Kazushige Yamaguchi,et al.  Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  M. Monden,et al.  Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma. , 2002, Liver.

[14]  H. Kiyokawa,et al.  The Cell Cycle-Regulatory CDC25A Phosphatase Inhibits Apoptosis Signal-Regulating Kinase 1 , 2001, Molecular and Cellular Biology.

[15]  H. Wada,et al.  Clinical significance of p21 expression in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. H. Kim,et al.  Amplified CDK2 and cdc2 activities in primary colorectal carcinoma , 1999, Cancer.

[17]  J. Bockaert,et al.  Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors , 1999, Oncogene.

[18]  N. Mailand,et al.  Rapid destruction of human Cdc25A in response to DNA damage. , 2000, Science.

[19]  S. Elledge,et al.  Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. , 2001, Cancer research.

[20]  J. Ritter Tumors of the Lower Respiratory Tract: Atlas of Tumor Pathology , 1996 .

[21]  F. Kaye,et al.  RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer , 2002, Oncogene.

[22]  J. Jen,et al.  Serial analysis of gene expression in non-small cell lung cancer. , 1998, Cancer research.

[23]  R. Figlin,et al.  Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. , 1993, Oncogene.

[24]  J. Forteza,et al.  Tissue concentrations of prothymosin alpha: a novel proliferation index of primary breast cancer. , 1993, European journal of cancer.

[25]  Masakazu Ueda,et al.  TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas , 2002, Hepatology.

[26]  A. Baldi,et al.  Expression of p21 in non small cell lung cancer relationship with PCNA. , 2000, Anticancer research.

[27]  Anu Gupta,et al.  Study of the G2/M cell cycle checkpoint in irradiated mammary epithelial cells overexpressing Cul-4A gene. , 2002, International journal of radiation oncology, biology, physics.

[28]  Y. Inayama,et al.  High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. , 2001, Lung cancer.

[29]  E. Lam,et al.  DP and E2F proteins: coordinating transcription with cell cycle progression. , 1994, Current opinion in cell biology.

[30]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Okamoto,et al.  Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. , 1996, International journal of cancer.

[32]  K. Parang,et al.  Current targets for anticancer drug discovery. , 2003, Current drug targets.

[33]  H. Friess,et al.  Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  L. Neckers,et al.  Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. , 2002, Journal of the National Cancer Institute.

[35]  F. Salvi,et al.  Radiation-induced gadd45 expression correlates with clinical response to radiotherapy of cervical carcinoma. , 2000, International journal of radiation oncology, biology, physics.

[36]  K. Yanagisawa,et al.  Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers , 2000, Oncogene.

[37]  H. Koeffler,et al.  Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. , 2001, Cancer research.

[38]  A. Papavassiliou,et al.  Transcription factor E2F‐1 acts as a growth‐promoting factor and is associated with adverse prognosis in non‐small cell lung carcinomas , 2002, The Journal of pathology.

[39]  C. Heldin,et al.  Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. , 2002, Immunology letters.

[40]  C. Croce,et al.  Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. , 1995, Cancer research.

[41]  Q. Xue,et al.  Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung , 2002, Pathology international.

[42]  E. Liu,et al.  BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents , 2001, Oncogene.

[43]  A. Giordano,et al.  p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. , 1998, American journal of respiratory cell and molecular biology.

[44]  S. Irniger Cyclin destruction in mitosis: a crucial task of Cdc20 , 2002, FEBS letters.

[45]  J. Kofron,et al.  Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. , 2003, Science.

[46]  R. Makuch,et al.  myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. , 1987, The Journal of clinical investigation.

[47]  E. Brambilla,et al.  Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors , 2002, Oncogene.

[48]  M. Volm,et al.  Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. , 1997, British Journal of Cancer.

[49]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[50]  V. N. Nguyen,et al.  Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. , 2000, Acta histochemica.

[51]  P. Zhou,et al.  UV-damaged DNA-binding Proteins Are Targets of CUL-4A-mediated Ubiquitination and Degradation* , 2001, The Journal of Biological Chemistry.

[52]  A. Miyauchi,et al.  Expression of p57/Kip2 protein in normal and neoplastic thyroid tissues. , 2002, International journal of molecular medicine.

[53]  J. Bartek,et al.  Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression , 1996, Molecular and cellular biology.

[54]  J. Bartek,et al.  Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. , 1995, Cancer research.

[55]  T. Huang,et al.  Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis. , 1997, Cancer research.

[56]  J. Battey,et al.  Molecular genetic analysis reveals chromosomal deletion, gene amplification, and autocrine growth factor production in the pathogenesis of human lung cancer. , 1986, Cold Spring Harbor Symposia on Quantitative Biology.

[57]  S. Miyoshi,et al.  Disruption of the RB pathway and cell‐proliferative activity in non‐small‐cell lung cancers , 1998, International journal of cancer.

[58]  E. Brambilla,et al.  The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. , 1998, Cancer research.

[59]  S. Jiang,et al.  Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. , 1998, The American journal of pathology.

[60]  Wei Zhang,et al.  Interaction of CR6 (GADD45γ) with Proliferating Cell Nuclear Antigen Impedes Negative Growth Control* , 2001, The Journal of Biological Chemistry.

[61]  Y. Yatabe,et al.  Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  H. Sasaki,et al.  Expression of the Prothymosin-α Gene as a Prognostic Factor in Lung Cancer , 2001, Surgery Today.

[63]  G E Moore,et al.  Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. , 1991, Cancer research.

[64]  W. Kuo,et al.  The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. , 1998, Cancer research.

[65]  K. Vareli,et al.  Nuclear distribution of prothymosin alpha and parathymosin: evidence that prothymosin alpha is associated with RNA synthesis processing and parathymosin with early DNA replication. , 2000, Experimental cell research.

[66]  G. Hannon,et al.  Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. , 1995, Cancer research.

[67]  G. Jianhua,et al.  A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers. , 1998, Cancer letters.

[68]  A. Gartel,et al.  p21—Negative Regulator of the Cell Cycle , 1996, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[69]  W. Benedict,et al.  Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  J. Battey,et al.  Amplification, expression and rearrangement of c-myc and N-myc oncogenes in human lung cancer. , 1984, Current topics in microbiology and immunology.

[71]  F. Khuri,et al.  Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. , 2000, Cancer research.

[72]  Dong Hoon Kim,et al.  Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. , 2003, Journal of biochemistry and molecular biology.

[73]  T. Kameya,et al.  Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas , 2003, The Journal of pathology.

[74]  Gregory R. Grant,et al.  Generation of patterns from gene expression data by assigning confidence to differentially expressed genes , 2000, Bioinform..

[75]  Carl W. Miller,et al.  Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors , 2002, Genes, chromosomes & cancer.

[76]  C. Mathew,et al.  The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer. , 1999, Genomics.

[77]  H. Sasaki,et al.  Elevated plasma thymosin-alpha1 levels in lung cancer patients. , 1997, European Journal of Cardio-Thoracic Surgery.

[78]  Carl W. Miller,et al.  Molecular analysis of a family of cyclin‐dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non‐small cell lung cancers , 1995, Molecular carcinogenesis.

[79]  É. Szabó,et al.  Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[80]  L. Mao,et al.  Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. , 1998, Cancer research.

[81]  C. W. Lee,et al.  Functional interaction between DP-1 and p53 , 1996, Molecular and cellular biology.

[82]  Scott E. Kern,et al.  Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers , 1996, Nature Genetics.

[83]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[84]  S. Elledge,et al.  Human cyclin F. , 1994, The EMBO journal.